Zhejiang Medicine Co., Ltd. (SHA:600216)
China
· Delayed Price · Currency is CNY 14.70
+0.09 (0.62%)
Apr 29, 2026, 3:00 PM CST
Zhejiang Medicine Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 751.31 | 873.38 | 1,161 | 429.64 | 539.57 | 1,045 | Upgrade
|
| Depreciation & Amortization | 710.95 | 710.95 | 723.01 | 724.98 | 681.6 | 587.57 | Upgrade
|
| Other Amortization | 87.31 | 87.31 | 3.54 | 2.64 | 3.75 | 0.08 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.08 | 0.08 | -3.09 | -330.16 | -3.31 | 7.95 | Upgrade
|
| Asset Writedown & Restructuring Costs | 32.1 | 32.1 | 96.4 | 15.81 | 12.8 | 46.19 | Upgrade
|
| Loss (Gain) From Sale of Investments | -7.49 | -7.49 | 29.6 | 28.59 | 56.51 | -93.54 | Upgrade
|
| Provision & Write-off of Bad Debts | -3.67 | -3.67 | 12.55 | 0.15 | -2.94 | 10.63 | Upgrade
|
| Other Operating Activities | -71.74 | 11.14 | 31.24 | -76.42 | -73.46 | 58.32 | Upgrade
|
| Change in Accounts Receivable | 144.04 | 144.04 | -759.44 | -29.42 | -161.98 | -402.19 | Upgrade
|
| Change in Inventory | 32.7 | 32.7 | -347.26 | -263.73 | -330.7 | -760.57 | Upgrade
|
| Change in Accounts Payable | -6.17 | -6.17 | 305.37 | 101.7 | -218.05 | 577.5 | Upgrade
|
| Change in Other Net Operating Assets | 11.9 | 11.9 | 13.69 | 37.47 | 33.35 | 42.24 | Upgrade
|
| Operating Cash Flow | 1,681 | 1,886 | 1,223 | 634.31 | 520.6 | 1,137 | Upgrade
|
| Operating Cash Flow Growth | 11.68% | 54.15% | 92.86% | 21.84% | -54.20% | -9.55% | Upgrade
|
| Capital Expenditures | -473.62 | -446.47 | -689.14 | -796.87 | -975.99 | -939.6 | Upgrade
|
| Sale of Property, Plant & Equipment | 1.93 | 1.87 | 200.49 | 174.48 | 7.2 | 6.97 | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | -140.73 | Upgrade
|
| Divestitures | - | - | - | - | 9.12 | - | Upgrade
|
| Investment in Securities | -148.85 | 71.95 | 14.08 | 102.02 | -40.46 | 39.13 | Upgrade
|
| Other Investing Activities | -19.5 | 0.71 | 1.07 | 0.78 | 1.75 | 1.98 | Upgrade
|
| Investing Cash Flow | -640.04 | -371.95 | -473.5 | -518.59 | -971.15 | -983.69 | Upgrade
|
| Long-Term Debt Issued | - | 695 | 520 | 600 | 660.74 | 580 | Upgrade
|
| Long-Term Debt Repaid | - | -577.69 | -573.63 | -600.34 | -726.21 | -700.43 | Upgrade
|
| Net Debt Issued (Repaid) | 160.31 | 117.31 | -53.63 | -0.34 | -65.47 | -120.43 | Upgrade
|
| Issuance of Common Stock | - | - | - | - | 59.95 | - | Upgrade
|
| Repurchase of Common Stock | -200 | -200 | -29 | -1.29 | - | - | Upgrade
|
| Common Dividends Paid | -375.69 | -376.69 | -170.31 | -191.91 | -351.09 | -260.06 | Upgrade
|
| Other Financing Activities | 97.62 | 56.52 | -2.38 | 52.12 | 400.53 | 450.25 | Upgrade
|
| Financing Cash Flow | -317.75 | -402.86 | -255.32 | -141.43 | 43.91 | 69.75 | Upgrade
|
| Foreign Exchange Rate Adjustments | 36.64 | 90.29 | 11.27 | 47.64 | 76.01 | -79.84 | Upgrade
|
| Net Cash Flow | 759.67 | 1,201 | 505.75 | 21.93 | -330.62 | 142.88 | Upgrade
|
| Free Cash Flow | 1,207 | 1,439 | 534.15 | -162.56 | -455.39 | 197.05 | Upgrade
|
| Free Cash Flow Growth | 42.64% | 169.45% | - | - | - | -72.68% | Upgrade
|
| Free Cash Flow Margin | 13.69% | 16.21% | 5.70% | -2.09% | -5.61% | 2.16% | Upgrade
|
| Free Cash Flow Per Share | 1.26 | 1.51 | 0.56 | -0.17 | -0.47 | 0.20 | Upgrade
|
| Cash Interest Paid | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | - | Upgrade
|
| Cash Income Tax Paid | 443.37 | 398.06 | 352.56 | 163.05 | 344.56 | 384.41 | Upgrade
|
| Levered Free Cash Flow | 1,099 | 1,355 | 414.84 | -20.65 | -899.57 | 1,076 | Upgrade
|
| Unlevered Free Cash Flow | 1,115 | 1,370 | 431.32 | -2.94 | -878.88 | 1,100 | Upgrade
|
| Change in Working Capital | 181.98 | 181.98 | -830.45 | -160.92 | -693.92 | -525.86 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.